Figure 1
Kaplan-Meier curve of tumor control in experimental and control group.
Table 1
Patients’ characteristics, treatment procedure and response to treatment of patients included in experimental group
| Patient | Gender | Age (years) | Creatinine (μmol/L) | Total bleomycin dose (IU) | Electrodes used | Last follow up (months after ECT) | Histology | Maximum tumor size (mm) | Recurrence of tumor (months after ECT) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 86 | 84 | 20,000 | Needle row | 30 | BCC BCC | 20 8 | |
| 2 | M | 67 | 108 | 24,000 | Needle row | 29 | BCC BCC | 10 8 | |
| 3 | M | 80 | 106 | 21,000 | Needle row | 20 | BCC | 30 | 10 |
| 4# | M | 82 | 66 | 20,000 | Needle row | 2 * | SCC SCC SCC | 10 6 10 | |
| 5 | M | 92 | 88 | 20,000 | Needle row | 25 | BCC BCC BCC | 25 15 15 | 25 25 |
| 6 | M | 79 | 67 | 20,000 | Plate | 34 | BCC BCC BCC BCC | 80 20 20 10 | 24 |
| 7 | F | 78 | 83 | 20,000 | Needle row | 30 | BCC | 15 | |
| 8# | M | 76 | 144 | 21,000 | Needle row | 6 * | SCC SCC SCC | 20 27 35 | |
| 9 | F | 86 | 74 | 17,500 | Needle row | 19 * | BCC | 25 | |
| 10 | M | 80 | 81 | 21,000 | Needle row | 28 | BCC | 10 | 13 |
| 11 | M | 85 | 42 | 20,000 | Needle row | 24 * | BCC | 50 | 3 |
| 12 | M | 83 | 94 | 19,000 | Needle row | 28 | BCC SCC | 7 7 | 4 |
[i] BCC = basal cell carcinoma; ECT = electrochemotherapy; F = female; M = male; SCC = squamous cell carcinoma; * = patient deceased; # = excluded from analysis
Table 2
Patients’ characteristics, treatment procedure and response to treatment of patients included in control group
| Patient | Gender | Age (years) | Creatinine (μmol/L) | Total bleomycin dose (IU) | Electrodes used | Last follow-up (months after ECT) | Histology | Maximum tumor size (mm) | Recurrence of tumor (months after ECT) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 65 | 68 | 30,000 | Needle row | 39 | BCC | 22 | |
| 2 | F | 74 | 86 | 26,000 | Needle row | 55 | BCC | 15 | |
| 3 | M | 83 | 129 | 28,000 | Plate | 19 * | BCC | 12 | |
| BCC | 32 | 7 | |||||||
| BCC | 10 | 7 | |||||||
| 4 | M | 81 | 78 | 27,000 | Needle row | 37 | BCC | 10 | |
| BCC | 5 | ||||||||
| BCC | 6 | ||||||||
| BCC | 4 | ||||||||
| 5 | F | 82 | 73 | 24,000 | Plate | 41 | BCC | 9 | 6 |
| BCC | 5 | ||||||||
| BCC | 11 | ||||||||
| 6# | M | 88 | 142 | 30,000 | Plate | 2 | BCC | 39 | |
| 7 | F | 69 | 84 | 23,000 | Finger | 46 | BCC | 15 | |
| 8 | F | 82 | DM | 24,000 | Hexagonal | 41 | BCC | 50 | |
| BCC | 7 | ||||||||
| BCC | 20 | 18 | |||||||
| 9 | F | 89 | 69 | 23,000 | Plate | 48 | BCC | 6 | |
| BCC | 5 | ||||||||
| BCC | 6 | ||||||||
| 10 | M | 65 | DM | 27,000 | Plate | 31 | BCC | 24 | |
| 11# | F | 70 | DM | 27,000 | Plate | 4 | BCC | 7 | |
| 12 | M | 78 | DM | 23,000 | Plate | 46 | BCC | 15 | |
| 13 | F | 74 | 52 | 24,000 | Needle row | 38 | BCC | 15 | |
| 14 | F | 89 | 54 | 25,000 | Plate | 48 | BCC | 21 | |
| BCC | 22 | ||||||||
| 15 | M | 67 | DM | 30,000 | Plate | 11 | SCC | 25 | |
| 16 | M | 85 | 100 | 24,000 | Needle row | 15 * | SCC | 45 |
[i] BCC = basal cell carcinoma; ECT = electrochemotherapy; F = female, M = male; SCC = squamous cell carcinoma; * = patient deceased; # = excluded from analysis